|Bid||52.79 x 1800|
|Ask||52.80 x 1800|
|Day's Range||52.72 - 53.51|
|52 Week Range||49.31 - 86.31|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||9.91|
|Earnings Date||Jun 27, 2019|
|Forward Dividend & Yield||1.76 (3.33%)|
|1y Target Est||57.90|
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens, a provider of trusted care in communities since 1901, is helping to raise awareness about skin health this summer with a series of programs to educate the public about skin cancer risks and the importance of early detection. Through interactive, community-focused events featuring dermatologists, knowledgeable pharmacists and specially-trained beauty consultants, Walgreens will offer free resources to help people protect their skin during the summer months. According to The Skin Cancer Foundation, skin cancer is one of the most common forms of cancer in the United States, and also one of the most preventable.
CVS Health (NYSE: CVS) faces two distinct headwinds that are putting pressure on CVS stock.First, markets are cautious over the drug store and drug manufacturing market as the government pressure all players to lower drug prices.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDoubts over CVS' acquisition of Aetna are adding more distractions for management in the near-term. With CVS stock testing the $51.72 yearly low on at least five occasions since March, what will it take for the stock to rebound?CVS reported first-quarter earnings of $1.62 and also raised its full-year adjusted EPS guidance to $6.75 to $6.90. This is up from the previous guidance of $6.68 to $6.88 a share.The Q1 beat and improved outlook are due largely to the inclusion of managed care operations. The company also included revenue from SilverScript Medicare Part D, which contributed $17.9 billion of revenue for the quarter. * 5 Stocks to Buy for $20 or Less Better synergies with Aetna also contributed favorably to the higher outlook. CVS expects it will exceed its target savings of $750 million in 2020. It found synergies stemming from the elimination of duplication in corporate and operational functions, medical cost savings such as formulary alignment, and purchasing efficiencies. By 2022, CVS forecast saving $1.5 billion to $2 billion, well above its deal synergy targets.CVS forecast cash flow of between $9.8 billion and $10.3 billion and will use $4.2 billion to $4.6 billion to pay down its debt. Its debt/equity of 1.25 times is above that of Cigna Corporation (NYSE: CI) at 0.95, and UnitedHealth (NYSE: UNH) at 0.74, both of which are attractive investments.Despite the less favorable debt/equity, CVS Health pays a dividend yielding 3.69%. Walgreens Boots Alliance (NASDAQ: WBA) also has a lower debt/equity of 0.73 but its dividend is slightly lower too, at 3.35%. Value Investing OpportunityInvestors who think that CVS has deep value with a forward P/E of 7.6 times are betting the company will mitigate near-term headwinds hurting the business. In Q1, prescription growth of 5.5% benefited from the support of clinical care programs and network relationships.The company will improve margins in its long-term care business. And with PBM, the idea of a net cost pricing model is resonating with clients. Some clients will adapt to this offering while CVS expects its uptake improving in 2020 and beyond.CVS is testing new approaches in delivering and managing health care. Its Houston HealthHub stores bring health care services into communities. Meeting people where they are should drum up more business.Still, CVS will primarily use data and analytics to deliver such services at the best cost. Plus, it has a long-term vision of seamlessly connecting consumer experiences across digital and clinical interactions.Initial results from the Houston stores are encouraging. The locations are performing better than expected, giving the company the green light to expand the HealthHUB model. RisksAlthough CVS Health's market share stood at 26.2% in the first quarter, front store comparable sales rose just 0.4%. Adjusted operating income from Retail/Long-term care dropped 18.9%. Reimbursement pressure, higher legal costs, and higher expenses weighed on Q1 results.Should costs grow higher than expected in the course of this year, CVS may lower its guidance. Fortunately, synergies from the Aetna acquisition are tracking higher than the company expected. HealthHUB is resonating well with customers. This is encouraging the company to add more net new items in the front-store of the self-care and wellness areas. Along with expanding MinuteClinic services, CVS will continue expanding the interactions between pharmacists and patients who need it most. ValuationThe 14 analysts offering a price target on CVS stock have an average price of $70.18, which is ~30% above the recent closing price of $54.17. Conversely, investors could assume a perpetuity growth rate of between 5% and 6% in the 5Y DCF Growth Exit model. In this scenario, the fair value of CVS stock is $63 a share, implying an upside of 16% for investors (per finbox.io). Your CVS Stock TakeawayThe CVS and Aetna deal is getting challenged. Investors could bet that the court lets the deal close. More importantly, CVS is already reaping the benefits of the combination by cutting costs. By delivering better services to the customers it services, the company will keep growing.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities.Compare Brokers The post CVS Stock Has More Going for It Than Just a 3.69% Dividend Yield appeared first on InvestorPlace.
Walgreens Boots Alliance (WBA) closed at $52.80 in the latest trading session, marking a -0.02% move from the prior day.
Walgreens Boots Alliance Inc NASDAQ/NGS:WBAView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is contracting Bearish sentimentShort interest | PositiveShort interest is low for WBA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold WBA had net inflows of $3.41 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managersâ€™ Index (PMI) data, output in the Consumer Servicesis falling. The rate of decline is significant relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Every fund investor would like to see the manager of the actively managed funds that they own beat the market every year, but they've been left wanting for well over a decade. The lack of consistent outperformance on the part of large-cap active managers (the main contributors to the Ultimate Stock-Pickers concept) has been well documented by the S&P Indices Versus Active Funds (SPIVA) U.S. Scorecard. While five-year results have been poor for active management, there are some recent bright spots, particularly in large-cap value.
The Dow Jones Industrial Average has gained nearly 12% so far in 2019. It doesn't seem like a whole heck of a lot, but considering the topsy-turvey markets of 2019, it's a pretty strong lift. That gain was driven by the majority of the Dow 30 as most of the stocks in the DJIA index contributed to its postive year-to-date gain.Microsoft (NASDAQ:MSFT) is the biggest winner of the bunch, gaining more than 30%. But owing to the odd price-weighted nature of the index, it's likely Visa (NYSE:V), with a 28% gain and a higher share price, that has been the biggest driver behind the Dow's gains.Not every component of the Dow Jones today has had a strong year, though. Five of the index's 30 stocks have declined so far this year. But not all of them make the list of the five worst Dow Jones stocks in 2019, which we'll recount in greater detail going forward.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today For reasons that go beyond pure performance, these five components have had the roughest year so far, which means they have the most to prove in the second half of 2019. Walgreens (WBA)Source: Mike Mozart via FlickrWalgreens (NASDAQ:WBA) is the easiest pick on the list. That's somewhat ironic considering that Walgreens is one of the index's newest members, replacing General Electric (NYSE:GE) just last year. WBA stock far and away has had the worst performance in 2019: its 22.6% decline is almost exactly twice as steep as that of the index's second-biggest decliner. WBA touched a five-year low late last month before a modest rally in recent weeks.As I wrote in April, disappointing store-level execution clearly has been a factor. But what might be more worrisome for WBA is that the entire retail pharmacy industry seems to under threat. Shares of rival CVS Health (NYSE:CVS), too, have touched a multi-year low.Smaller Rite Aid (NYSE:RAD) continues to plunge, with a hefty debt load adding to the pressure. Front-end sales aren't growing, and in pharmacy higher generic prices are compressing already-thin margins.WBA stock is cheap, now at less than 9x forward earnings. But right now, Walgreens looks a lot like most other retailers - and that will have to change for Walgreens stock to reverse its performance in not only 2019, but the last few years. Dow Inc. (DOW)Source: Roy Luck via Flickr (modified)It's a little unfair to put Dow Inc. (NYSE:DOW) on this list. DOW shares actually have gained 6% since they were spun off from what is now (again) DuPont (NYSE:DD) on April 1st.But DOW is part of the DowDuPont spinoff, a hugely complicated financial engineering project that was supposed to create real value for shareholders. It hasn't happened. DWDP shareholders received one share of Corteva (NYSE:CTVA) and one share of DOW for every three DowDuPont shares they owned. At current prices, that totals about $50 in value. DWDP shares closed 2018 near $54 - after declining 25% last year.This was a case where many value investors saw significant upside. Yet trade war concerns and post-spin trading have led DWDP to destroy value, at least so far. DOW and its former siblings still have time, and room, to rally. But a lot of smart investors likely see the YTD performance as among the most disappointing in their portfolios. Intel (INTC)Source: Shutterstock Performance-wise, Intel (NASDAQ:INTC) hasn't been a bad stock in 2019. It's underperformed the market, but a 0.5% decline actually turns very slightly positive when accounting for dividend payments.Still, 2019 hasn't been a good year for Intel. It's suffering chip shortages. It's still behind in 10nm -- and about four years late. Rival Advanced Micro Devices (NASDAQ:AMD) is gobbling up market share in CPUs. Apple (NASDAQ:AAPL) settled with Qualcomm (NASDAQ:QCOM) in large part because Intel couldn't move quick enough to get the iPhone to 5G.Intel still is a behemoth in the chip space, and the company still has time to right its ship. With INTC stock at barely 10x earnings, there's upside if and when that happens. But the company's performance so far this year inspires little confidence, which has been much weaker than a flattish stock price would imply. 3M (MMM)Source: Shutterstock The 11.4% decline in 3M (NYSE:MMM) shares so far this year is the second-worst performance in the Dow. But no component has posted a worse quarterly report than 3M did with its Q1 release in late April. 3M stock plunged 13%, its worst one-day decline in over 30 years. The drop was big enough to on its own pull the index down over 100 points.MMM stock still hasn't recovered: it would drop nearly another 20% in the following weeks before bottoming of late. And there's a case for the stock after the big decline, as James Brumley argued earlier this month. A 3.4% dividend yield helps the argument, and 3M's diversified business should allow it to ride out any further near-term or market volatility.Still, Q1 was an obvious concern: stocks like 3M don't fall 25% in a matter of weeks for no reason. And it was the automotive and Chinese markets that led to the poor quarter. Neither seems likely to rebound sharply all that soon. At the very least, it's going to take a lot more than one good quarter for 3M to make back what it lost after Q1. Pfizer (PFE)Source: Shutterstock It's a bit unfair to put Pfizer (NYSE:PFE) on this list. Pfizer certainly hasn't had a terrible year. PFE stock is down 2.6%, the third-worst performance in the index. But drugmakers generally underperform in bull markets, and many drug stocks have done worse in 2019. A 3.4% dividend yield offsets most of those losses anyhow.That said, Pfizer hasn't had a great year, either. Rival (and fellow Dow component) Merck (NYSE:MRK) has gained 8%-plus. And it's hard not to get the sense that PFE, which traded mostly sideways for over three years in the middle of the decade, is back to being stagnant. There doesn't seem to much of a catalyst on the horizon to change the Pfizer story, while external pressures on the industry continue to mount.It's true that, even this year, PFE shareholders could have done worse. But given that 25 Dow Jones stocks are up YTD, it's obvious they could have done better.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post The 5 Worst Dow Jones Stocks So Far in 2019 appeared first on InvestorPlace.
Walgreens opened Monday at $52.57 with a loss of 23.1% year to date and in bear market territory 39.1% below its Dec. 4 intraday high of $86.31. The stock's weekly slow stochastic reading ended last week at 8.03, well below 10.00, making the stock technically "too cheap to ignore." Walgreens is also fundamentally cheap with a P/E ratio of 8.66 and a dividend yield of 3.33%, according to Macrotrend. Walgreens is in a period of transformation from being just a pharmacy chain to offering services to help cancer patients.
Walgreens and Greater Than AIDS are working with health departments, HIV/AIDS service organizations, and other community organizations to provide free HIV testing and information at select Walgreens stores in more than 260 cities on National HIV Testing Day (NHTD), Thursday, June 27 between 10 am – 7 pm (local time). HIV testing is recommended as part of routine health care, yet many Americans are not being tested as often as advised. According to the Centers for Disease Control and Prevention (CDC), one in seven people living with HIV in the U.S. today are unaware of their status.
Overall, the first quarter has been relatively strong for retailers, so let's look at what investors should expect from Kroger to see if they should consider buying KR stock heading into its Q1 earnings release.
Women feel guilty about taking time for self-care, and many say their responsibility to take care of others is the reason.
With more than 2,700 branded locations nationwide, this grocer plans to introduce topical CBD products in a third of all states.
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $52.12, marking a -1.44% move from the previous day.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Walgreens Boots Alliance, Inc. New York, June 12, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Walgreens Boots Alliance, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Kroger Co (NYSE: KR ) is the latest company to introduce CBD products to its U.S. store shelves. The grocery chain's corporate affairs manager for its Michigan division, Rachel Hurst, said the company ...